Latest and Past News
-
Important CHS survey on gene therapy
Companies will likely make submissions to Health Canada for approval of gene therapies for hemophilia A and B in the next 6-12 months. To best...
-
Blood donation: dispelling a myth
Eligibility for blood donation in Canada is constantly evolving. For many years, the sexual partners of people with bleeding disorders were deferred from blood donation....
-
Hearing the patient voice on therapy choice: FVIII or non-FVIII
by the Canadian Association of Nurses in Hemophilia Care – Ontario Region* and Sarah Crymble, Ontario Hemophilia Provincial Coordinator Treatment for patients with hemophilia A...
-
Memorial art – helping to prevent future calamity … helping to heal
by Rick Waines, British Columbia In 1983 I was 17 and attended my first WFH meeting in Stockholm, Sweden, and at the opening plenary Dr....
-
Return of Octostim spray delayed until late 2024
In a letter to the European Haemophilia Consortium dated May 31, 2022, Ferring Pharmaceuticals informed the bleeding disorder community that Octostim (desmopressin) Nasal Spray 1.5...
-
CHS Board of Directors
Meet the CHS Board of Directors! From left to right: First row: Cyril Boulila, Wendy Quinn, Leanne Owen. Back row: Dr. Lawrence Jardine, Derek Klatt,...
-
WFH 2022 Congress experience from a social worker’s perspective
by Karen Mantyka, Social worker, Saskatchewan Bleeding Disorders Program This year marked the 35th WFH World Congress, which was held in Montreal, Canada where thousands...
-
The CHS appoints new CEO
CLICK HERE to read the official announcement from CHS President, Wendy Quinn.
-
2021 CHS Annual Report
Please CLICK HERE to access the 2021 CHS Annual Report. Should you want to consult the complete Financial Statements, you can do so by clicking...
-
CHS reacts to Health Canada decision on relaxing donor selection criteria
April 28, 2022 (Montreal) – “The Canadian Hemophilia Society (CHS) is disappointed that Health Canada has not followed our advice regarding the changes to donor...
-
Committed BC health care providers receive two awards
by Wendy Quinn, CHS President A few days ago I received an e-mail with the subject “Exciting news and accomplishments in BC.” I immediately opened...
-
CBS supplier contracts for rFVIII and rFIX take effect April 4
March 30, 2022, Ottawa – Canadian Blood Services’ contracts with suppliers of recombinant factor VIII and IX for the 2022-2025 period take effect on April...
-
The 10 key takeaways from CHS advocacy efforts to obtain access to emicizumab (Hemlibra)
by David Page, CHS National Director of Health Policy The Canadian Hemophilia Society (CHS), its chapters and members have expended great efforts to advocate for...
-
Update on products in the pipeline
Updated charts for products in the pipeline have been uploaded on the CHS website. The CHS publishes four charts, one each for clotting factor concentrates, inhibitor...